|
12 |
Alteogen Files PCT Patent Application for ADC Subcutaneous Formulation Technology |
Alteogen |
2025-09-26 |
|
11 |
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) |
Alteogen |
2025-09-17 |
|
10 |
Alteogen's CEO Soon Jae Park Interview Article (The Korea Economic Daily) |
Alteogen |
2025-08-19 |
|
9 |
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, ‘EYLUXVI® (ALT-L9)’ |
Alteogen |
2025-07-28 |
|
8 |
Alteogen Signs License Agreement with AstraZeneca for Subcutaneous Oncology Therapy Development |
Alteogen |
2025-03-17 |
|
7 |
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme Platform |
Alteogen |
2024-11-14 |
|
6 |
Alteogen Announces Amendment to License Agreement with MSD |
Alteogen |
2024-02-22 |
|
5 |
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile |
Alteogen |
2023-09-05 |
|
4 |
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products |
Alteogen |
2023-01-02 |
|
3 |
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products |
Alteogen |
2021-01-07 |
